Recent News

CEO Corner - Thursday, June 13, 2019 iCubate is proud to be a part of ASM Microbe 2019. Many of us will be on site at the Moscone Center in San Francisco for this outstanding scientific conference. At ASM Microbe 2019, there are many ways to learn why iCubate is right for your lab. These include: 1) attend iCubate's workshop @ 1pm on Thursday, June 20th; 2) stop by booth 4241 at 1pm on Friday, June 21st to see how easy it is to use iCubate assays; 3) Wes Coleman will demonstrate operating the iCubate platform - or you can try it for yourself at 1pm on Saturday, June 22nd at booth 4241; and 4) on Sunday, June 23rd @ 1pm at booth 4241, join the discussion about the value iCubate brings to the clinical laboratory. Look forward to seeing you in San Francisco.   Carter Wells CEO, iCubate  

CAD Lays the Groundwork for iCubate’s DNA Testing Devices

September 24, 2018 - iCubate, according to the company’s website, is a molecular diagnostic company with a novel multiplex polymerase chain reaction (mPCR) technology. It is also an integrated platform for infectious disease diagnostics and research applications. The iC-Cassette. (Image courtesy of iCubate.) To shed light on what this all means, and to explain how the company designed this system, we spoke to James Bullington, chief technology officer (CTO) of LSINC to learn all about it. LSINC is a product development, engineering design and consultancy firm, which has been helping to design and produce iCubate’s products since 2008. After completing ...
Read More

“Providing Molecular Diagnostic Solutions One Cassette at a Time”

Huntsville, Ala. March 7, 2018 – iCubate®, Inc., an innovative molecular diagnostic device company, announced today that it will host a workshop presentation at the South Central Association of Clinical Microbiology meeting in French Lick, Indiana. The presentation, “Providing Molecular Diagnostic Solutions One Cassette at a Time,” will be on Thursday, March 8 at 10 am at the French Lick Resort, 8670 West State Street. Among the items discussed will be the importance of timely, accurate results when detecting bloodstream infection, clinical laboratory requirements and iCubate’s recently cleared iC-GPC Assay™. The iC-GPC Assay is used for the rapid detection of ...
Read More

iCubate® to present FDA cleared pathogenic bacteria detection system at AMP Meeting

Huntsville, Ala. November 13, 2017 – iCubate®, Inc., an innovative molecular diagnostic device company, announced today that it will host a workshop presentation at the Association of Molecular Pathology (AMP) meeting in Salt Lake City, Utah. The presentation will be on Wednesday, November 15 at 4 pm at the Calvin L. Rampton Salt Palace Convention Center. The presentation, titled “Clinical Application of the iCubate Gram-Positive Cocci (iC-GPC) Assay,” will feature key opinion leaders and iCubate leadership. The iC-GPC Assay™, used for the rapid detection of pathogenic bacteria associated with bloodstream infections, earned U.S. FDA clearance earlier this year. Among those participating in the workshop presentation ...
Read More

iCubate Receives CE Mark for the iC-GPC Assay™

iCubate Receives CE Mark for the iC-GPC Assay™ for use on the iC-System™ iCubate’s platform and initial assay now available for European clinical laboratory use Huntsville, Ala. August 22, 2017 – iCubate, Inc., an innovative molecular diagnostic device company, announced today that it has received CE Mark for its iCubate platform, the iC-System™, and its first clinical assay, the iC-GPC Assay™, used for the rapid detection of pathogenic bacteria associated with bloodstream infection (BSI). The CE Mark paves the way for iCubate to begin market integration into the European Union. “Obtaining CE Mark for iCubate’s platform and initial assay achieves ...
Read More

iCubate® Earns FDA Clearance

iCubate® Earns FDA Clearance for A Unique Diagnostic Solution for the diagnosis of Bloodstream Infections iCubate’s “ARM­PCR” technology, integrated platform and initial assay now available for United States Clinical Laboratories Huntsville, Ala. August 10, 2017 – iCubate®, Inc., an innovative molecular diagnostic device company, announced today that it has earned U.S. Food and Drug Administration (FDA) clearance for its iCubate platform, the iC-­System™, and its first clinical assay, the iC­-GPC Assay™, used for the rapid detection of pathogenic bacteria associated with bloodstream infection (BSI). The FDA clearance allows iCubate to market, sell and distribute the cleared products to U.S. Clinical ...
Read More

iCubate® forms Scientific Advisory Board

Huntsville, Ala. — October 6, 2016 —iCubate®, a molecular diagnostic company, has formed a Scientific Advisory Board to advance the company’s goal of developing and marketing technologies and products for personalized diagnostics. The advisory board will work with iCubate’s board and management team to ensure the company continues to develop innovative products that meet market demand and are positioned for long-term growth and success. “iCubate is privileged to have these individuals as part of our Scientific Advisory Board. The advice and guidance offered by this group of distinguished scientists will be of tremendous value as we position the company’s future ...
Read More

FmIH function & proof of concept bladder infections can be reduced!

Researchers have identified a potential way to prevent chronic urinary tract infections (UTIs). Their research points to a key protein that bacteria use to latch onto the bladder and cause UTIs, according to scientists at Washington University School of Medicine in St. Louis. Vaccinating mice against the protein reduces the ability of bacteria to cause severe disease. The study, published Sept. 22 in Cell Host & Microbe, suggests that targeting this protein may prevent the most serious consequences of a very common infection. "Our findings reveal how bacteria have evolved a mechanism to colonize the bladder in order to persist ...
Read More

iCubate receives Innovation Award at Alabama Launchpad

EDPA’s Alabama Launchpad presents Innovation Awards, celebrates entrepreneurship from Alabama NewsCenter on Vimeo. Andrew Yang, founder and CEO of Venture for America, said during his keynote address that Birmingham is the best-kept secret in the innovation and entrepreneurship world because of the level of support and activity he has witnessed in the Magic City. “It’s phenomenal to see the energy and spirit of entrepreneurship really coming into its own here in Birmingham,” Yang said. Venture for America, or VFA, works with existing innovation companies and startups by offering fellowships to recent college graduates to help them learn what it takes ...
Read More
Loading...